Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

NCT07425782 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

216

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Consolidation Therapy
Venentoclax
High Risk
Hematopoietic Stem Cell Transplant (HSCT)

Interventions

DRUG: Ara-C Group
DRUG: VEN/AZA condsolidation

Sponsor

The First Affiliated Hospital of Soochow University